Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

CNS 7Sarcoma 4Other hematologic neoplasm 4Other neoplasm 2Myeloid 2Gynecologic 2Gastrointestinal 2Classical hematology 2Thoracic 1Plasma cell 1Lymphoid 1Genitourinary 1Endocrine 1Breast 1

Conditions

Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × DNA Methylation × Breast × Clear all
NCT00671476 2014-01-10

Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery

National Cancer Institute (NCI)

Phase NA Unknown
30 enrolled
Breast

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡